Ajay Nooka MD, MPH

Department of Hematology and Medical Oncology
Professor

(404) 778-1900
anooka@emory.edu

Overview

Ajay K. Nooka, MD, MPH, FACP, serves as director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nooka also serves as medical director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University. An Emory Healthcare network physician since 2011, Dr. Nooka is a board certified hematologist specializing in the treatment of patients with multiple myeloma.

Dr. Nooka is a clinical member of the Cancer Prevention and Control research program at Winship Cancer Institute. He serves on the steering committee of the Multiple Myeloma Research Consortium.

Dr. Nooka attended Medical School at the Andhra Medical College in Visakhapatnam, India. He earned his Master's in Public Health at the University of Texas School of Public Health. He then went on to complete his residency at Canton Medical Education Foundation in Canton, Ohio. He did his fellowship at the Winship Cancer Institute of Emory University in Atlanta, GA.

Dr. Nooka's research interests include integrating genomic and clinical data on a uniform platform and to interpret in a meaningful way to risk-stratify myeloma; and evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. He also focuses on cancer epidemiology.

Dr. Nooka serves on the editorial board for The American Journal of Clinical Oncology, Journal of Hematological Malignancies, Lymphoma and Chronic Lymphocytic Leukemias. He is an adhoc Journal Reviewer for Annals of Oncology, Cancer, Oncology, Leukemia Research, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, European Journal of Cancer, Current-Oncology, Indian Journal of Medical Research and International Journal of Hematology.

Academic Appointment

Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MPH from University of Texas Health Science Center at Houston, Houston
Bachelor of Medicine and Bachelor of Surgery (MBBS) from Andhra Medical College
No Degree from All India Senior School Certificate Examination (AISSCE)

Research

Focus

My research interests include improving induction therapies in myelomas and other lymphoproliferative disorders; with special focus on autologous and allogeneic transplantation.

Publications

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.
Br J Haematol
04/15/2025 Authors: Biran N; Dhakal B; Niesvizky R; Lentzsch S; Bhutani D; McKay JT; Vesole DH; Nooka A; Paul B; Hari PN
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.
Clin Lymphoma Myeloma Leuk
04/11/2025 Authors: Varga C; Robinson M; Gupta V; Hofmeister CC; Nooka AK; Kaufman JL; Dhodapkar MV; Lonial S; Borden S; Ferreri C
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.
Blood Volume: 145 Page(s): 732 - 747
02/13/2025 Authors: Nair R; Vu AH; Freer AK; Bhatia KS; Wang D; Savani MR; Matulis SM; Lonial S; Jaye DL; Boise LH
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs.
Acta Haematol Volume: 148 Page(s): 135 - 147
01/01/2025 Authors: Barberio J; Lash TL; Nooka AK; Naimi AI; Patzer RE; Kim C
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Blood Volume: 144 Page(s): 2389 - 2401
12/05/2024 Authors: Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Blood Volume: 144 Page(s): 2375 - 2388
12/05/2024 Authors: Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG
Improving reporting of infection events in clinical trials.
Blood Adv Volume: 8 Page(s): 5927 - 5928
11/26/2024 Authors: Ludwig H; Munshi NC; Terpos E; Raje N; Moreau P; Nooka A
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
NPJ Vaccines Volume: 9 Page(s): 201
10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
Blood Cancer J Volume: 14 Page(s): 186
10/21/2024 Authors: van de Donk NWCJ; Bahlis N; Costa LJ; Mateos M-V; Nooka AK; Perrot A; Garfall AL; Thaman P; Qi K; Uhlar C
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.
Blood Adv Volume: 8 Page(s): 4979 - 4982
09/24/2024 Authors: Ludwig H; Munshi NC; Terpos E; Schweitzer I; Raje N; Moreau P; Nooka A
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Blood Cancer J Volume: 14 Page(s): 159
09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lancet Oncol Volume: 25 Page(s): e374 - e387
08/01/2024 Authors: Lin Y; Qiu L; Usmani S; Joo CW; Costa L; Derman B; Du J; Einsele H; Fernandez de Larrea C; Hajek R
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Cancer Volume: 130 Page(s): 2629 - 2641
08/01/2024 Authors: Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos M-V
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol Volume: 204 Page(s): 2227 - 2232
06/01/2024 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes TM; Holstein SA; Anderson LD; Badros A
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components.
Blood Adv Volume: 8 Page(s): 2290 - 2299
05/14/2024 Authors: Wheeler AP; Snyder EL; Refaai M; Cohn CS; Poisson J; Fontaine M; Sehl M; Nooka AK; Uhl L; Spinella PC
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Br J Haematol Volume: 204 Page(s): 1801 - 1810
05/01/2024 Authors: Mohty M; Bahlis NJ; Nooka AK; DiBonaventura M; Ren J; Conte U
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol Volume: 25 Page(s): e205 - e216
05/01/2024 Authors: Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gllego Prez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cancer Volume: 130 Page(s): 886 - 900
03/15/2024 Authors: Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Clin Lymphoma Myeloma Leuk Volume: 24 Page(s): 194 - 202
03/01/2024 Authors: Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos M-V; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Lancet Haematol Volume: 11 Page(s): e216 - e227
03/01/2024 Authors: Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A
Shrinking the divide: improving myeloma CART access.
Blood Adv Volume: 8 Page(s): 248 - 250
01/09/2024 Authors: Nooka AK; Hartley-Brown MA; Anderson KC; Lonial S
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Blood Adv Volume: 8 Page(s): 194 - 206
01/09/2024 Authors: Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T
Glcksklee, the Quad, and High-Risk Myeloma.
J Clin Oncol Volume: 42 Page(s): 1 - 3
01/01/2024 Authors: Nooka AK; Kaufman JL; Lonial S
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol Volume: 20 Page(s): 1221 - 1235
01/01/2024 Authors: Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
Blood Cancer J Volume: 13 Page(s): 191
12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK
Addressing the disparities: the approach to the African American patient with multiple myeloma.
Blood Cancer J Volume: 13 Page(s): 189
12/18/2023 Authors: Bhutani M; Blue BJ; Cole C; Badros AZ; Usmani SZ; Nooka AK; Bernal-Mizrachi L; Mikhael J
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Oncologist Volume: 28 Page(s): 1055 - 1063
12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer Volume: 129 Page(s): 3746 - 3760
12/01/2023 Authors: Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah A-O; Trudel S; Chari A; Libby EN
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Clin Cancer Res Volume: 29 Page(s): 4784 - 4796
12/01/2023 Authors: Chung DJ; Shah N; Wu J; Logan B; Bisharat L; Callander N; Cheloni G; Anderson K; Chodon T; Dhakal B
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Nat Med Volume: 29 Page(s): 2259 - 2267
09/01/2023 Authors: Lesokhin AM; Tomasson MH; Arnulf B; Bahlis NJ; Miles Prince H; Niesvizky R; Rodrguez-Otero P; Martinez-Lopez J; Koehne G; Touzeau C
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
JCO Oncol Pract Volume: 19 Page(s): 793 - 798
09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
J Clin Invest Volume: 133
08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.
Haematologica Volume: 108 Page(s): 2249 - 2254
08/01/2023 Authors: Dhakal B; Zhang M-J; Burns LJ; Tang X; Meyer C; Mau L-W; Nooka AK; Stadtmauer E; Micallef IN; McGuirk J
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Cancer Volume: 129 Page(s): 2035 - 2046
07/01/2023 Authors: Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
J Comp Eff Res Volume: 12 Page(s): e220186
06/01/2023 Authors: Krishnan A; Nooka AK; Chari A; Garfall AL; Martin TG; Nair S; Lin X; Qi K; Londhe A; Pei L
Cardiotoxicities of Cellular Therapies: A Practical Approach in a Sea of Uncertainty.
JCO Oncol Pract Volume: 19 Page(s): 343 - 344
06/01/2023 Authors: Mandawat A; Nooka AK
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol Volume: 19 Page(s): 811 - 818
04/01/2023 Authors: Moreau P; van de Donk NW; Nahi H; Oriol A; Nooka AK; Martin T; Rosinol L; Karlin L; Benboubker L; Mateos M-V
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med Volume: 388 Page(s): 1002 - 1014
03/16/2023 Authors: Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol Volume: 41 Page(s): 1600 - 1609
03/10/2023 Authors: Sonneveld P; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos M-V
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Blood Cancer Discov Volume: 4 Page(s): 106 - 117
03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
Blood Cancer J Volume: 13 Page(s): 29
02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol Volume: 18 Page(s): 4443 - 4456
12/01/2022 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes T; Holstein SA; Anderson LD; Badros A
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
Eur J Cancer Volume: 177 Page(s): 197 - 205
12/01/2022 Authors: Nowatzke J; Guedeney P; Palaskas N; Lehmann L; Ederhy S; Zhu H; Cautela J; Francis S; Courand P-Y; Deswal A
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
J Clin Oncol Volume: 40 Page(s): 3808 - 3816
11/20/2022 Authors: Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit.
Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S24 - S26
10/01/2022 Authors: Nooka AK; Lonial S
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
Sci Adv Volume: 8 Page(s): eabq5575
09/30/2022 Authors: Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
J Clin Oncol Volume: 40 Page(s): 3057 - 3064
09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
J Clin Oncol Volume: 40 Page(s): 3020 - 3031
09/10/2022 Authors: Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM
adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma.
Haematologica Volume: 107 Page(s): 2226 - 2231
09/01/2022 Authors: Nair R; Subramaniam V; Barwick BG; Gupta VA; Matulis SM; Lonial S; Boise LH; Nooka AK; Muthumalaiappan K; Shanmugam M
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med Volume: 387 Page(s): 495 - 505
08/11/2022 Authors: Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Blood Cancer J Volume: 12 Page(s): 115
08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
Carfilzomib 56mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.
Leuk Lymphoma Volume: 63 Page(s): 1887 - 1896
08/01/2022 Authors: Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e526 - e531
07/01/2022 Authors: Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components.
Transfusion Volume: 62 Page(s): 1365 - 1376
07/01/2022 Authors: Snyder EL; Wheeler AP; Refaai M; Cohn CS; Poisson J; Fontaine M; Sehl M; Nooka AK; Uhl L; Spinella P
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Blood Cancer J Volume: 12 Page(s): 63
04/13/2022 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes T; Holstein SA; Anderson LD; Badros A
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Pharmacotherapy Volume: 42 Page(s): 233 - 240
03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
medRxiv
01/23/2022 Authors: Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet Oncol Volume: 23 Page(s): 65 - 76
01/01/2022 Authors: Usmani SZ; Quach H; Mateos M-V; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma.
Cancer Volume: 127 Page(s): 4133 - 4136
11/15/2021 Authors: Nooka AK; Joseph NS; Lonial S
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer Volume: 127 Page(s): 4198 - 4212
11/15/2021 Authors: Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander N; Sborov D; Suvannasankha A
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
Blood Cancer Discov Volume: 2 Page(s): 600 - 615
11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants
Volume: 21 Page(s): S129 - S129
10/01/2021 Authors: Andrews J; Gleason C; Dhodapkar MV; Lonial S; Kaufman J; Nooka A
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer Volume: 21 Page(s): 993
09/06/2021 Authors: Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Blood Cancer J Volume: 11 Page(s): 149
09/03/2021 Authors: Ramasamy K; Nooka A; Quach H; Htut M; Popat R; Liedtke M; Tuchman SA; Laubach J; Gasparetto C; Chanan-Khan A
Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for >= 12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
Volume: 44 Page(s): 181 - 181
09/01/2021 Authors: Trautmann-Grill K; Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Sborov D; Zaugg BE; Popat R
Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Volume: 21 Page(s): S396 - S397
09/01/2021 Authors: Santapuram P; Rupji M; Graiser M; Waller E; Blum K; Allen P; Koff J; Heffner L; Lechowicz M; Lonial S
Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for >= 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Volume: 21 Page(s): S419 - S419
09/01/2021 Authors: Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Sborov D; Zaugg BE; Popat R; Degli Esposti S
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Br J Haematol Volume: 194 Page(s): 784 - 788
08/01/2021 Authors: Quach H; Nooka A; Samoylova O; Venner CP; Kim K; Facon T; Spencer A; Usmani SZ; Grosicki S; Suzuki K
Selinexor for the treatment of patients with previously treated multiple myeloma.
Expert Rev Hematol Volume: 14 Page(s): 697 - 706
08/01/2021 Authors: Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood Volume: 137 Page(s): 3604 - 3615
07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Blood Cancer J Volume: 11 Page(s): 116
06/18/2021 Authors: Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Future Oncol Volume: 17 Page(s): 1987 - 2003
06/01/2021 Authors: Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
Clin Cancer Res Volume: 27 Page(s): 3178 - 3189
06/01/2021 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Blood Cancer J Volume: 11 Page(s): 103
05/26/2021 Authors: Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Br J Haematol Volume: 193 Page(s): 561 - 569
05/01/2021 Authors: Hungria V; Beksac M; Weisel KC; Nooka AK; Masszi T; Spicka I; Munder M; Mateos M-V; Mark TM; Qi M
Maintenance Strategies for Myeloma: Is Bigger Always Better?
Cancer J Volume: 27 Page(s): 231 - 238
05/01/2021 Authors: Nooka AK; Joseph NS
Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
Volume: 193 Page(s): 53 - 54
04/01/2021 Authors: Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Sborov D; Zaugg BE; Popat R; Degli Esposti S
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Am J Hematol Volume: 96 Page(s): E68 - E71
03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Am J Cancer Res Volume: 11 Page(s): 3285 - 3293
01/01/2021 Authors: Cornell RF; Bishop MR; Kumar S; Giralt SA; Nooka AK; Larson SM; Locke FL; Raje NS; Lei L; Dong J
Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Blood Cancer J Volume: 10 Page(s): 125
12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S
Primary refractory multiple myeloma: a real-world experience with 85 cases.
Leuk Lymphoma Volume: 61 Page(s): 2868 - 2875
12/01/2020 Authors: Jurczyszyn A; Waszczuk-Gajda A; Castillo JJ; Krawczyk K; Stork M; Pour L; Usnarska-Zubkiewicz L; Potoczek S; Hus I; Davila Valls J
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Ophthalmol Ther Volume: 9 Page(s): 889 - 911
12/01/2020 Authors: Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Ophthalmol Ther Volume: 9 Page(s): 913 - 915
12/01/2020 Authors: Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ
Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Volume: 136
11/05/2020 Authors: Lonial S; Nooka A; Thulasi P; Badros AZ; Jeng BH; Callander NS; Sborov D; Zaugg BE; Popat R; Degli Esposti S
Role of clonoSEQ (R), a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
Volume: 136
11/05/2020 Authors: Nooka A; Bradley K; Joseph N; Hofmeister CC; Dhodapkar MV; Boise LH; Lonial S; Li S; Kaufman JL
Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
Volume: 136
11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center
Volume: 136
11/05/2020 Authors: Maples KT; Brechtelsbauer E; Pendexter J; Kaufman JL; Joseph N; Heffner L; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka A
Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
Volume: 136
11/05/2020 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.
JCO Oncol Pract Volume: 16 Page(s): e1169 - e1180
10/01/2020 Authors: Yu Y; Brown Wade N; Hwang AE; Nooka AK; Fiala MA; Mohrbacher A; Peters ES; Pawlish K; Bock C; Van Den Berg DJ
Pivotal DREAMM-2 Study: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) refractory to Proteasome Inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 Monoclonal Antibodies (mAbs)
Volume: 43 Page(s): 102 - 103
10/01/2020 Authors: Weisel K; Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander N; Sborov D
DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
Volume: 43 Page(s): 103 - 104
10/01/2020 Authors: Weisel K; Popat R; Lonial S; Lee H; Badros A; Trudel S; Nooka A; Chari A; Abdallah A-O; Callander N
DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
Volume: 43 Page(s): 109 - 110
10/01/2020 Authors: Weisel K; Lonial S; Lee H; Badros A; Trudel S; Nooka A; Chari A; Abdallah A-O; Callander N; Sborov D
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Leukemia Volume: 34 Page(s): 2430 - 2440
09/01/2020 Authors: Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D
Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics
Volume: 20 Page(s): S301 - S302
09/01/2020 Authors: Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander NS; Sborov DW; Suvannasankha A
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
J Hematol Oncol Volume: 13 Page(s): 115
08/20/2020 Authors: Weisel K; Spencer A; Lentzsch S; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin M-D; Bosi A
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 509 - 518
08/01/2020 Authors: Mateos M-V; Sonneveld P; Hungria V; Nooka AK; Estell JA; Barreto W; Corradini P; Min C-K; Medvedova E; Weisel K
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
J Immunother Cancer Volume: 8
07/01/2020 Authors: Shah N; Aiello J; Avigan DE; Berdeja JG; Borrello IM; Chari A; Cohen AD; Ganapathi K; Gray L; Green D
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
JCI Insight Volume: 5
06/18/2020 Authors: Bar N; Costa F; Das R; Duffy A; Samur M; McCachren S; Gettinger SN; Neparidze N; Parker TL; Bailur JK
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1928 - 1937
06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 351 - 357
06/01/2020 Authors: Mikhael J; Noonan KR; Faiman B; Gleason C; Nooka AK; Costa LJ; Jagannath S; Richardson PG; Siegel D; Chari A
A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Volume: 29
06/01/2020 Authors: Du Z; Weinhold N; Song GC; Rand KA; Van den Berg DJ; Hwang AE; Sheng X; Hom V; Ailawadhi S; Nooka AK
KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
Volume: 38
05/20/2020 Authors: Jagannath S; Lin Y; Goldschmidt H; Reece DE; Nooka AK; Otero PR; Matsue K; Shah N; Anderson LD; Wilson K
Real-world outcomes of venetoclax refractory multiple myeloma patients.
Volume: 38
05/20/2020 Authors: Maples KT; Kaufman JL; Gupta VA; Joseph N; Heffner LT; Hofmeister CC; Dhodapkar M; Matulis SM; Boise L; Lonial S
Efficacy of daratumumab plus SOC versus SOC in myeloma induction regimens, by risk-stratification: Meta-analysis of phase III randomized control trials.
Volume: 38
05/20/2020 Authors: Joseph N; Hofmeister CC; Dhodapkar M; Boise L; Lonial S; Behera M; Kaufman JL; Nooka AK
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
Blood Cancer J Volume: 10 Page(s): 40
04/14/2020 Authors: Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omed P
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Nat Commun Volume: 11 Page(s): 1228
03/06/2020 Authors: Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A
Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT)Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401
Volume: 26 Page(s): S62 - S63
03/01/2020 Authors: Avigan DE; Shah N; Logan B; Zhu J; Bisharat L; Callander NS; Chodon T; Dhakal B; Efebera YA; Geller N
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol Volume: 21 Page(s): 207 - 221
02/01/2020 Authors: Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander N; Lendvai N; Sborov D
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Blood Adv Volume: 4 Page(s): 181 - 190
01/14/2020 Authors: Du Z; Weinhold N; Song GC; Rand KA; Van Den Berg DJ; Hwang AE; Sheng X; Hom V; Ailawadhi S; Nooka AK
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Haematologica Volume: 105 Page(s): 468 - 477
01/01/2020 Authors: Mateos M-V; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L
Approaches to Treating Multiple Myeloma, Now and Moving Forward.
JCO Oncol Pract Volume: 16 Page(s): 15 - 16
01/01/2020 Authors: Gupta VA; Joseph NS; Nooka AK
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood Cancer J Volume: 9 Page(s): 94
11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
Volume: 134
11/13/2019 Authors: Kachuri L; Du Z; Weinhold N; Song G; Rand KA; Van den Berg D; Hwang A; Sheng X; Hom V; Ailawadhi S
The Role of Proteasome Activator PA28 alpha in Multiple Myeloma
Volume: 134
11/13/2019 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman JL; Nooka AK; Gupta VA; Dhodapkar MV; Boise LH; Lonial S
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 134
11/13/2019 Authors: Bernal-Mizrachi L; Nooka AK; Heffner L; Cole CE; Ye JC; Vij R; Hofmeister CC; Rushton J; Chen Z; Chang Z
Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study
Volume: 19 Page(s): E118 - E119
10/01/2019 Authors: Vogl DT; Nooka A; Gavriatopoulou M; Yee A; Huff C; Moreau P; Dingli D; Cole C; Richardson PG; Dimopoulos MA
Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study
Volume: 19 Page(s): E117 - E118
10/01/2019 Authors: Gavriatopoulou M; Vogl DT; Nooka A; Dingli D; Cole C; Moreau P; Huff C; Yee A; Dimopoulos MA; Lonial S
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 19 Page(s): E243 - E244
10/01/2019 Authors: Bernal L; Nooka A; Cole C; Heffner LT; Ye JC; Vij R; Chen Z; Zhang C; Rushton J; Munevver C
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Volume: 125 Page(s): 2991 - 3000
09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med Volume: 381 Page(s): 727 - 738
08/22/2019 Authors: Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S
Daratumumab in multiple myeloma.
Cancer Volume: 125 Page(s): 2364 - 2382
07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Registering a CD38 antibody upfront for multiple myeloma.
Lancet Volume: 394 Page(s): 3 - 4
07/06/2019 Authors: Hofmeister CC; Nooka A; Kaufman JL; Lonial S
Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma
Volume: 79
07/01/2019 Authors: Joseph N; Gupta VA; Hofmeister C; Gleason C; Heffner LT; Jonathan KL; Boise LH; Dhodapkar MD; Lonial S; Nooka AK
Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma
Volume: 79
07/01/2019 Authors: Bajpai R; Achreja A; Wei C; Siddiqa A; Matulis SM; Gupta V; McBrayer SK; Mittal A; Rupji M; Chen H-R
Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
Volume: 37
05/20/2019 Authors: Weisel K; Spencer A; Lentzsch S; Avet-Loiseau H; Mark TM; Spicka I; Bosi A; Hungria VTM; Cavo M; Lee J-J
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Leukemia Volume: 33 Page(s): 1291 - 1296
05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
JCI Insight Volume: 5
04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Nat Commun Volume: 10 Page(s): 1911
04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer Volume: 125 Page(s): 416 - 423
02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Cancer Volume: 125 Page(s): 185 - 193
01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.
Clin Infect Dis Volume: 68 Page(s): 196 - 203
01/07/2019 Authors: Mullane KM; Winston DJ; Nooka A; Morris MI; Stiff P; Dugan MJ; Holland H; Gregg K; Adachi JA; Pergam SA
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J Volume: 9 Page(s): 3
01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma.
Cancer J Volume: 25 Page(s): 19 - 31
01/01/2019 Authors: Nooka AK; Lonial S
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Nat Commun Volume: 9 Page(s): 5341
12/17/2018 Authors: Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Haematologica Volume: 103 Page(s): 2079 - 2087
12/01/2018 Authors: Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin M-D; Bosi A
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Future Oncol Volume: 14 Page(s): 3111 - 3121
12/01/2018 Authors: Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
JAMA Oncol Volume: 4 Page(s): e183267
12/01/2018 Authors: Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
Volume: 132
11/29/2018 Authors: Barwick BG; Neri P; Bahlis N; Nooka AK; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Cancer Volume: 124 Page(s): 4342 - 4349
11/15/2018 Authors: Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Cancer Volume: 124 Page(s): 4358 - 4365
11/15/2018 Authors: Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Leukemia Volume: 32 Page(s): 2305
10/01/2018 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
J Oncol Pract Volume: 14 Page(s): 561 - 564
09/01/2018 Authors: Chang A; Nasti TH; Khan MK; Parashar S; Kaufman JL; Boise LH; Lonial S; Ahmed R; Nooka AK
Impact of Hematologic Parameters in Newly Diagnosed Multiple Myeloma Patients on Long-Term Outcomes
Volume: 18 Page(s): S257 - S257
09/01/2018 Authors: Joseph N; Nooka A
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population
Volume: 18 Page(s): S250 - S251
09/01/2018 Authors: Schmidt T; Mina R; Joseph N; Gay F; Nooka A; Kastritis E; Spada S; Kaufman J; Montefusco V; Gilestro M
How Does Genetics and MRD Impact Treatment or Doesn't It?
Volume: 18 Page(s): S69 - S72
09/01/2018 Authors: Nooka AK; Lonial S
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
J Oncol Pract Volume: 14 Page(s): 414 - 422
07/01/2018 Authors: Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
A meta-analysis of genome-wide association studies of multiple myeloma among African Americans
Volume: 78
07/01/2018 Authors: Du Z; Song C; Rand K; Weinhold N; Van den Berg D; Hwang A; Sheng X; Hom V; Ailawadhi S; Nooka AK
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Volume: 36
05/20/2018 Authors: Cornell RF; Locke FL; Bishop MR; Orlowski RZ; Larson SM; Borrello I; Giralt S; Kumar S; Nooka AK; Raje NS
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Volume: 36
05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK
Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
Volume: 36
05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
J Clin Oncol Volume: 36 Page(s): 859 - 866
03/20/2018 Authors: Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J
14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Leukemia Volume: 32 Page(s): 744 - 751
03/01/2018 Authors: Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A
Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
Volume: 24 Page(s): S135 - S136
03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S
A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma
Volume: 130
12/07/2017 Authors: Gupta VA; Barwick B; Newman S; Keats JJ; Auclair D; Matulis S; Rossi MR; Nooka AK; Kaufman JL; Lonial S
Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Volume: 130
12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A
A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants
Volume: 130
12/07/2017 Authors: Du Z; Weinhold N; Van den Berg D; Hwang A; Sheng X; Hom V; Ailawadhi S; Nooka AK; Singhal S; Pawlish K
Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax
Volume: 130
12/07/2017 Authors: Bajpai R; Wei C; Matulis S; Nooka AK; McBrayer S; Lonial S; Gupta VA; Boise LH; Shanmugam M
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Leukemia Volume: 31 Page(s): 2695 - 2701
12/01/2017 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
CD86 regulates myeloma cell survival.
Blood Adv Volume: 1 Page(s): 2307 - 2319
11/28/2017 Authors: Gavile CM; Barwick BG; Newman S; Neri P; Nooka AK; Lonial S; Lee KP; Boise LH
Development of GLUT4-selective antagonists for multiple myeloma therapy.
Eur J Med Chem Volume: 139 Page(s): 573 - 586
10/20/2017 Authors: Wei C; Bajpai R; Sharma H; Heitmeier M; Jain AD; Matulis SM; Nooka AK; Mishra RK; Hruz PW; Schiltz GE
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.
Blood Adv Volume: 1 Page(s): 1848 - 1853
09/26/2017 Authors: Shah SP; Nooka AK; Lonial S; Boise LH
High-risk Multiple Myeloma: Definition and Management.
Clin Lymphoma Myeloma Leuk Volume: 17S Page(s): S80 - S87
07/01/2017 Authors: Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK
EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
Volume: 102 Page(s): 168 - 169
06/26/2017 Authors: Weisel K; Lentzsch S; Mateos MV; Hungria V; Munder M; Nooka A; Mark T; Quach H; Scott EC; Lee J-J
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
Volume: 129 Page(s): 3033 - 3037
06/01/2017 Authors: Sullivan HC; Gerner-Smidt C; Nooka AK; Arthur CM; Thompson L; Mener A; Patel SR; Yee M; Fasano RM; Josephson CD
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.
Infect Control Hosp Epidemiol Volume: 38 Page(s): 651 - 657
06/01/2017 Authors: Shah NN; McClellan W; Flowers CR; Lonial S; Khoury H; Waller EK; Langston A; Nooka AK
EVALUATION OF SURVIVAL OUTCOMES OF POST-FRONTLINE ANTI-MYELOMA TREATMENTS IN MULTIPLE MYELOMA PATIENTS BASED ON DATA FROM SEER-MEDICARE DATABASE
Volume: 20 Page(s): A214 - A214
05/01/2017 Authors: Nooka A; Voorhees P; Kumar S; Mehra M; Lam A; Slavcev M; Ukropec J; Dasgupta A
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Blood Volume: 129 Page(s): 1969 - 1979
04/06/2017 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR
Volume: 17 Page(s): E133 - E133
02/01/2017 Authors: Lentzsch S; Nooka A; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott E; Chanan-Khan A; Horvath N
Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients
Volume: 17 Page(s): E68 - E69
02/01/2017 Authors: Joseph N; Kaufman J; Boise L; Almaula D; Langston A; Waller E; Khoury H; Heffner LT; Lonial S; Nooka A
Survival Outcomes of Younger (<= 50 years) Myeloma Patients
Volume: 17 Page(s): E119 - E119
02/01/2017 Authors: Almaula D; Joseph N; Kaufman JL; Heffner LT; Liu Y; Zhang C; Boise L; Lonial S; Nooka A
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant
Volume: 128
12/02/2016 Authors: Kumar P; Joseph N; Almaula D; Boise LH; Kaufman JL; Gleason C; Lonial S; Nooka AK
HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)
Volume: 128
12/02/2016 Authors: Gragert L; Hwang A; Bernal-Mizrachi L; Ailawadhi S; Singhal S; Vandenberg DJ; Sheng X; Stram A; Conti DV; Rand KA
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor
Volume: 128
12/02/2016 Authors: Mateos M-V; Estell J; Barreto W; Corradini P; Min C-K; Medvedova E; Qi M; Schecter J; Amin H; Qin X
B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma
Volume: 128
12/02/2016 Authors: Gupta VA; Newman S; Bahlis NJ; Keats JJ; Matulis S; Rossi MR; Auclair D; Nooka AK; Kaufman JL; Lonial S
Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 128
12/02/2016 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Peterkin D; Lonial S; Richardson PG
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Cancer Epidemiol Biomarkers Prev Volume: 25 Page(s): 1609 - 1618
12/01/2016 Authors: Rand KA; Song C; Dean E; Serie DJ; Curtin K; Sheng X; Hu D; Huff CA; Bernal-Mizrachi L; Tomasson MH
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.
Cancer Volume: 122 Page(s): 3207 - 3214
10/15/2016 Authors: Nooka AK; Behera M; Lonial S; Dixon MD; Ramalingam SS; Pentz RD
Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
ANNALS OF ONCOLOGY Volume: 27
10/01/2016 Authors: Weisel K; Palumbo A; Chanan-Khan A; Nooka AK; Spicka I; Masszi T; Beksac M; Hungria V; Munder M; Mateos M-V
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Oncotarget Volume: 7 Page(s): 59727 - 59741
09/13/2016 Authors: Shah SP; Nooka AK; Jaye DL; Bahlis NJ; Lonial S; Boise LH
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.
Leuk Lymphoma Volume: 57 Page(s): 2071 - 2076
09/01/2016 Authors: Jurczyszyn A; Olszewska-Szopa M; Hungria V; Crusoe E; Pika T; Delforge M; Leleu X; Rasche L; Nooka AK; Druzd-Sitek A
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med Volume: 375 Page(s): 754 - 766
08/25/2016 Authors: Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV
Is Maintenance Therapy for Everyone?
Clin Lymphoma Myeloma Leuk Volume: 16 Suppl Page(s): S139 - S144
08/01/2016 Authors: Nooka AK; Lonial S
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Oncogene Volume: 35 Page(s): 3955 - 3964
07/28/2016 Authors: Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Volume: 17 Page(s): 769 - 777
07/02/2016 Authors: Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH
Death by a thousand cuts: the slow demise of chemotherapy.
Cancer Volume: 122 Page(s): 1971 - 1973
07/01/2016 Authors: Nooka AK; Lonial S
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Am J Hematol Volume: 91 Page(s): 575 - 580
06/01/2016 Authors: Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias ALM; Vij R; Fiala MA
A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP
Volume: 101 Page(s): 82 - 82
06/01/2016 Authors: Trudel S; Spencer A; Sutherland H; O'Dwyer M; Huang SY; Stewart AK; Chari A; Rosenzwieg M; Nooka A; Rosenbaum C
PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
Volume: 101 Page(s): 340 - 341
06/01/2016 Authors: Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV
POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PROTEASOME INHIBITOR-EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCALATION, PHASE 1 TRIAL (MM-005)
Volume: 101 Page(s): 257 - 257
06/01/2016 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (ACE-MM-200 STUDY)
Volume: 101 Page(s): 524 - 525
06/01/2016 Authors: Niesvizky R; Richardson P; Gabrail N; Madan S; Yee A; Shain K; Hoffman J; Pagel J; Bensinger W; Nooka A
Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials.
Volume: 34
05/20/2016 Authors: Nooka AK; Kaufman JL; Lonial S
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Oncotarget Volume: 7 Page(s): 27753 - 27763
05/10/2016 Authors: Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J
Novel Combination Treatments in Multiple Myeloma.
Oncology (Williston Park) Volume: 30 Page(s): 451 - 465
05/01/2016 Authors: Nooka AK; Lonial S
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Leukemia Volume: 30 Page(s): 1086 - 1093
05/01/2016 Authors: Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
Myeloma Is Not a Single Disease.
J Oncol Pract Volume: 12 Page(s): 287 - 292
04/01/2016 Authors: Lonial S; Nooka AK
Meningeal Myelomatosis.
Volume: 12 Page(s): 187 - 188
02/01/2016 Authors: DeFilipp Z; Sahovic EA; Nooka AK
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital.
J Stem Cell Res Ther Volume: 6
01/01/2016 Authors: Yun HD; Dossul T; Bernal-Mizrachi L; Switchenko J; Ndibe C; Ibraheem A; Dixon MD; Langston AA; Nooka AK; Flowers CR
New Targets and New Agents in High-Risk Multiple Myeloma.
Volume: 35 Page(s): e431 - e441
01/01/2016 Authors: Nooka AK; Lonial S
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
J Med Econ Volume: 19 Page(s): 243 - 258
01/01/2016 Authors: Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y
Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States
Volume: 126
12/03/2015 Authors: Bikmal A; Radhakrishnan L; Nooka AK
Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Volume: 126
12/03/2015 Authors: Yee AJ; Laubach JP; Nooka AK; O'Donnell EK; Weller EA; Couture NR; Wallace EE; Burke JN; Harrington CC; Puccio-Pick M
Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Volume: 126
12/03/2015 Authors: Radhakrishnan L; Lonial S; Nooka AK
The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality
Volume: 126
12/03/2015 Authors: Radhakrishnan L; Lonial S; Nooka AK
Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 126
12/03/2015 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Lonial S; Richardson PG; Raje NS
Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Kendi ATK; Li Y; Obidike CO; Gleason C; Boise LH; Lonial S
Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Collins H; Gupta VA; Boise LH; Lonial S
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
Volume: 126
12/03/2015 Authors: Richardson PC; Hofmeister C; Raje NS; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
Description of the types and content of phase 1 clinical trial consent conversations in practice.
Clin Trials Volume: 12 Page(s): 567 - 574
12/01/2015 Authors: Wall L; Farmer ZL; Webb MW; Dixon MD; Nooka A; Pentz RD
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Volume: 21 Page(s): 2039 - 2051
12/01/2015 Authors: Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Transfusion Volume: 55 Page(s): 2351 - 2357
10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C
Targeting glucose and glutamine regulated BCL2 family members for multiple myeloma therapy
Volume: 75
08/01/2015 Authors: Bajpai R; Matulis SM; Wei C; Nooka AK; Boise LH; Shanmugam M
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.
J Biol Chem Volume: 290 Page(s): 14441 - 14453
06/05/2015 Authors: Mishra RK; Wei C; Hresko RC; Bajpai R; Heitmeier M; Matulis SM; Nooka AK; Rosen ST; Hruz PW; Schiltz GE
Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
Volume: 33
05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S
Treatment options for relapsed and refractory multiple myeloma.
Blood Volume: 125 Page(s): 3085 - 3099
05/14/2015 Authors: Nooka AK; Kastritis E; Dimopoulos MA; Lonial S
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
CANCER Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges.
Bone Marrow Transplant Volume: 50 Page(s): 465 - 468
03/01/2015 Authors: Zhang J; Mosunjac M; Moon A; Nooka A; Waller EK
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
Leuk Lymphoma Volume: 56 Page(s): 383 - 389
02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L
Novel combination approaches for myeloma.
Hematology Am Soc Hematol Educ Program Volume: 2015 Page(s): 286 - 293
01/01/2015 Authors: Lonial S; Nooka AK
Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Volume: 124
12/06/2014 Authors: Matulis S; Nooka AK; Von Hollen H; Kaufman JL; Lonial S; Boise LH
Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant
Volume: 124
12/06/2014 Authors: Pooja C; Nooka AK; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S; Bernal-Mizrachi L
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Volume: 124
12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW
Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies
BLOOD Volume: 124
12/06/2014 Authors: Bernal-Mizrachi L; Nooka AK; Pooja C; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S
Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
BLOOD Volume: 124
12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S
Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
BLOOD Volume: 124
12/06/2014 Authors: Wang ML; Nooka AK; Yee AJ; Thomas SK; O'Donnell E; Shah J; Weber DM; Kaufman JL; Lonial S; Avigan D
Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells
Volume: 124
12/06/2014 Authors: Gavile CM; Nooka AK; Lonial S; Lee KP; Boise LH
Risk Factors for Development of Myeloma: Role of Smoking and Alcohol
Volume: 124
12/06/2014 Authors: Nooka AK; Lonial S; Boise LH; Lechowicz MJ; Chen E
Transcriptional and Post-translational Regulation of the BcI-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S148 - S148
09/01/2014 Authors: Gupta VA; Matulis SM; Nooka AK; Kaufman JL; Lonial S; Boise LH
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
South Med J Volume: 107 Page(s): 497 - 500
08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S
Survival trends of myeloma patients in the new millennium.
Volume: 32
05/20/2014 Authors: Gleason C; Nooka AK; Langston AA; Shah NN; Kaufman JL; Lonial S
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
Volume: 32
05/20/2014 Authors: Richardson PG; Hofmeister C; Raje NS; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e59 - e63
04/01/2014 Authors: Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Leukemia Volume: 28 Page(s): 690 - 693
03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Lancet Oncol Volume: 15 Page(s): 333 - 342
03/01/2014 Authors: Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ
Simplified Technique for Administration of High Dose Melphalan
Volume: 20 Page(s): S291 - S292
02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Cancer Volume: 119 Page(s): 4119 - 4128
12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Oncology (Williston Park) Volume: 27 Suppl 3 Page(s): 11 - 18
12/01/2013 Authors: Nooka AK
Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Rossi MR; Newman S; Nooka AK; Kaufman JL; Bahlis NJ; Neri P; Matulis SM; Bernal-Mizrachi L; Gupta VA; Varma A
Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S
P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Shah SP; Gupta VA; Matulis SM; Nooka AK; Lonial S; Boise LH
Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Kaufman JL; Casbourne D; Hutcherson D; Maynard R; Waller EK; Lonial S; Langston A
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low alpha-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study
Volume: 122
11/15/2013 Authors: Lonial S; Shah JJ; Zonder J; Bensinger WI; Cohen AD; Kaufman JL; Nooka AK; Weber DM; Hilder B; Rush SA
Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS)
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Lonial S
Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample
Volume: 122
11/15/2013 Authors: Nooka AK; Kaufman JL; Shah NN; Langston A; Collins H; Boise LH; Lonial S
MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
Volume: 122
11/15/2013 Authors: Richardson PG; Hofmeister CC; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje N
Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
Volume: 122
11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Haematologica Volume: 98 Page(s): 1753 - 1761
11/01/2013 Authors: Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
ONKOLOGIE Volume: 36 Page(s): 39 - 40
10/01/2013 Authors: Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S
MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Volume: 98 Page(s): 97 - 98
06/12/2013 Authors: Richardson P; Hofmeister C; Siegel D; Lonial S; Laubach J; Efebera Y; Vesole D; Nooka A; Rosenblatt J; Raje N
ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
Volume: 98 Page(s): 598 - 598
06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
Volume: 31
05/20/2013 Authors: Richardson PGG; Hofmeister CC; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje NS
Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
Volume: 31
05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK
Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.
Volume: 31
05/20/2013 Authors: Duc QT; Langston AA; Waller EK; Simon M; Gleason C; Casbourne D; Fisher M; Kaufman JL; Flowers C; Lonial S
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
BRITISH JOURNAL OF HAEMATOLOGY Volume: 161 Page(s): 20 - 20
04/01/2013 Authors: Siegel DS; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K
Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation
Volume: 48 Page(s): S453 - S453
04/01/2013 Authors: Johnson HR; Nooka A; Kaufman J; Flowers C; Langston A; Graiser M; Plummer T; Lonial S; Waller E
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
Ann Oncol Volume: 24 Page(s): 441 - 448
02/01/2013 Authors: Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
Ann Oncol Volume: 24 Page(s): 441 - 448
02/01/2013 Authors: Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR
Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
Volume: 19 Page(s): S191 - S191
02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.
Oncology Volume: 85 Page(s): 197 - 203
01/01/2013 Authors: Kaseb AO; Shama M; Sahin IH; Nooka A; Hassabo HM; Vauthey J-N; Aloia T; Abbruzzese JL; Subbiah IM; Janku F
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.
Biomed Res Int Volume: 2013 Page(s): 929842
01/01/2013 Authors: Chinnadurai R; Waller EK; Galipeau J; Nooka AK
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Biologics Volume: 7 Page(s): 13 - 32
01/01/2013 Authors: Nooka A; Gleason C; Casbourne D; Lonial S
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status
Volume: 120
11/16/2012 Authors: Yim DB; Nooka AK; Martin JM; Lonial S
Sequential or combination therapy for multiple myeloma.
Expert Rev Hematol Volume: 5 Page(s): 533 - 545
10/01/2012 Authors: Nooka A; Lonial S
PLASMA CELL LEUKEMIA: SUSTAINED RESPONSES ARE POSSIBLE WITH INNOVATIVE TREATMENT STRATEGIES
Volume: 97 Page(s): 601 - 601
07/16/2012 Authors: Nooka A; Kaufman J; Muppidi S; Harvey R; Gleason C; Heffner L; Langston A; Casbourne D; Boise L; Lonial S
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S
Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
Curr Drug Deliv Volume: 9 Page(s): 41 - 51
01/01/2012 Authors: Reid E; Nooka A; Blackmon J; Lechowicz MJ
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 498 - 506
12/01/2011 Authors: Shenoy PJ; Malik N; Sinha R; Nooka A; Nastoupil LJ; Smith M; Flowers CR
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 118 Page(s): 1709 - 1710
11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
BLOOD Volume: 118 Page(s): 1691 - 1691
11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S
Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
Volume: 118 Page(s): 807 - 808
11/18/2011 Authors: Nooka AK; Behera M; Boise LH; Watson M; Kaufman JL; Lonial S
Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
Volume: 118 Page(s): 855 - 856
11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A
Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)
Volume: 118 Page(s): 351 - 351
11/18/2011 Authors: Sinha R; Byrtek M; DeJoubner NJ; Nooka AK; Taylor M; Cerhan JR; Friedberg J; Ziemiecki RM; Hirata JH; Link BK
Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 379 - 384
10/01/2011 Authors: Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report.
J Med Case Rep Volume: 5 Page(s): 372
08/12/2011 Authors: Rauf M; Gleason C; Nooka AK; Husman A; Waller EK
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
Cancer Volume: 117 Page(s): 2530 - 2540
06/01/2011 Authors: Shenoy PJ; Malik N; Nooka A; Sinha R; Ward KC; Brawley OW; Lipscomb J; Flowers CR
Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices.
J Clin Oncol Volume: 29 Page(s): 8036
05/20/2011 Authors: Nooka AK; DeJoubner NJ; Nabhan C; Zhou X; Taylor M; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Cancer Volume: 116 Page(s): 3143 - 3151
07/01/2010 Authors: Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Improving induction therapy in multiple myeloma.
Curr Hematol Malig Rep Volume: 5 Page(s): 119 - 128
07/01/2010 Authors: Nooka A; Gleason C; Lonial S
Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
Volume: 114 Page(s): 1496 - 1496
11/20/2009 Authors: Nooka AK; Kaufman JL; Heffner LT; Gleason CL; Lonial S
Supportive therapies in multiple myeloma.
J Natl Compr Canc Netw Volume: 7 Page(s): 971 - 979
10/01/2009 Authors: Gleason C; Nooka A; Lonial S
The importance of complete response in outcomes in myeloma.
Cancer J Volume: 15 Page(s): 465 - 472
01/01/2009 Authors: Nooka A; Kaufman J; Lonial S
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
J Bone Miner Res Volume: 23 Page(s): 826 - 836
06/01/2008 Authors: Hoff AO; Toth BB; Altundag K; Johnson MM; Warneke CL; Hu M; Nooka A; Sayegh G; Guarneri V; Desrouleaux K
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
Cancer Volume: 110 Page(s): 534 - 542
08/01/2007 Authors: Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.
Am J Gastroenterol Volume: 102 Page(s): 1016 - 1021
05/01/2007 Authors: Shaib YH; El-Serag HB; Nooka AK; Thomas M; Brown TD; Patt YZ; Hassan MM
Bilateral adrenal hemorrhage: an overlooked cause of hypotension.
J Emerg Med Volume: 32 Page(s): 167 - 169
02/01/2007 Authors: Picolos MK; Nooka A; Davis AB; Raval B; Orlander PR
Osteonecrosis of the jaw or maxilla after intravenous bisphosphonates for multiple myeloma and breast cancer: Long-term follow-up shows a slow rate of healing.
Volume: 108 Page(s): 370B - 370B
11/16/2006 Authors: Hu MI; Hoff AO; Toth B; Altundag K; Johnson M; Warneke C; Nooka A; Sayegh G; Guarneri V; Desrouleaux K
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy.
J Clin Oncol Volume: 24 Page(s): 8528
06/20/2006 Authors: Hoff AO; Toth BB; Altundag K; Guarneri V; Adamus A; Nooka AK; Sayegh GG; Johnson MM; Gagel RF; Hortobagyi GN
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy.
Volume: 20 Page(s): S55 - S55
09/01/2005 Authors: Hoff AO; Toth B; Altundag K; Guarneri V; Nooka A; Desrouleaux K; Klein M; Adamus A; Sayegh G; Worthing A
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Cancer Volume: 103 Page(s): 749 - 755
02/15/2005 Authors: Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
Volume: 20 Page(s): P61 - P61
01/01/2005 Authors: Hoff AO; Toth BB; Altundag K; Adamus A; Nooka A; Desrouleaux K; Cui J; Klein MJ; Gagel RF; Hortobagyi GN
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Cancer Volume: 101 Page(s): 578 - 586
08/01/2004 Authors: Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey J-N; Ellis LM; Schnirer II; Wolff RA